



Original Effective Date: 08/01/2018
Current Effective Date: 09/01/2024
Last P&T Approval/Version: 07/31/2024
Next Review Due By: 07/2025
Policy Number: C14649-A

Triptodur (triptorelin pamoate)

PRODUCTS AFFECTED

Triptodur (triptorelin pamoate)

COVERAGE POLICY

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide Molina Healthcare complete medical rationale when requesting any exceptions to these guidelines.

Documentation Requirements:

Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational, or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive.

DIAGNOSIS:

Central precocious puberty (CPP)

REQUIRED MEDICAL INFORMATION:

This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. If a drug within this policy receives an updated FDA label within the last 180 days, medical necessity for the member will be reviewed using the updated FDA label information along with state and federal requirements, benefit being administered and formulary preferencing. Coverage will be determined on a case-by-case basis until the criteria can be updated through Molina Healthcare, Inc. clinical governance. Additional information may be required on a case-by-case basis to allow for adequate review. When the requested drug product for coverage is dosed by weight, body surface area or other member specific measurement, this data element is required as part of the medical necessity review. The Pharmacy and Therapeutics Committee has determined that the drug benefit shall be a mandatory generic and that generic drugs will be dispensed whenever available.

A. CENTRAL PRECOCIOUS PUBERTY:

1. Documented diagnosis of central precocious puberty and member is currently less than 13 years old

Molina Healthcare, Inc. confidential and proprietary © 2024

This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare. This page contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with Molina Healthcare.

Drug and Biologic Coverage Criteria

AND

2. Documentation of an onset of secondary sexual characteristics with one of the following: Females ≤ 8 years of age OR Males ≤ 9 years of age
AND
3. Confirmation of diagnosis as defined by ONE of the following: (a) Pubertal basal level of luteinizing hormone (based on laboratory reference ranges) OR (b) Pubertal luteinizing hormone in response to a GnRH stimulation test OR (c) Bone age advanced one year beyond chronological age [DOCUMENTATION REQUIRED]

CONTINUATION OF THERAPY:

A. CENTRAL PRECOCIOUS PUBERTY:

1. Documented disease response as indicated by lack of progression or stabilization of secondary sexual characteristics, decrease in height velocity, and improvement in final height prediction
AND
2. Prescriber attests to or clinical reviewer has found no evidence of intolerable adverse effects or drug toxicity (e.g., psychiatric events, convulsions, hyperglycemia, etc.)
AND
3. Member is not currently older than age 12 OR prescriber has provided contributing factors that may include, bone age and height age, predicted height, and planned discontinuation plan or date.

DURATION OF APPROVAL:

Initial authorization: 22.5 mg intramuscular every 24 weeks, once for 24 weeks, Continuation of Therapy: 12 months

PRESCRIBER REQUIREMENTS:

Prescribed by, or in consultation with a pediatric endocrinologist. [If prescribed in consultation, consultation notes must be submitted with initial request and reauthorization requests]

AGE RESTRICTIONS:

2 years of age and older

QUANTITY:

22.5 mg IM every 24 weeks

PLACE OF ADMINISTRATION:

The recommendation is that injectable medications in this policy will be for pharmacy or medical benefit coverage and the intramuscular injectable products administered in a place of service that is a non-hospital facility-based location.

DRUG INFORMATION

ROUTE OF ADMINISTRATION:

Intramuscular Injection

DRUG CLASS:

LHRH/GNRH Agonists Analog Pituitary Suppressants

FDA-APPROVED USES:

Indicated for the treatment of pediatric patients 2 years and older with central precocious puberty
E30.1 Precocious puberty, E30.8 Other disorders of puberty

COMPENDIAL APPROVED OFF-LABELED USES:

MOLINA REVIEWER NOTE: For Utah Marketplace and Mississippi Medicaid please see Appendix.

APPENDIX

APPENDIX:

Reserved for State specific information. Information includes, but is not limited to, State contract language, Medicaid criteria and other mandated criteria.

State Specific Information

State Marketplace

Utah (Source: [State of Utah](#))

For hormone therapy requests for members <18 years of age, refer to [Hormone Therapy for Gender Dysphoria MUT C24947-A](#)

For all GnRH agent requests, refer to [Gonadotropin-releasing hormone \(GnRH\) MHUT C24948-A](#)

State Medicaid

Mississippi (Source: [State of Mississippi](#))

MS H.B. No. 1125 Regulate Experimental Adolescent Procedures (REAP) Act (2022): "Section 2. (f) (i) "Gender transition procedures" means any of the following medical or surgical services performed for the purpose of assisting an individual with a gender transition:

1. Prescribing or administering puberty-blocking drugs;
2. Prescribing or administering cross-sex hormones...

Section 2. (f) (ii) "Gender transition procedures" do not include:

1. Services to persons born with a medically verifiable disorder of sex development, including a person with external sex characteristics that are irresolvably ambiguous, such as those born with forty-six (46) XX chromosomes with virilization, forty-six (46) XY chromosomes with undervirilization, or having both ovarian and testicular tissue;
2. Services provided when a physician has otherwise diagnosed a disorder of sexual development that the physician has determined through genetic or biochemical testing that the person does not have normal sex chromosome structure, sex steroid hormone production, or sex steroid hormone action;
3. The treatment of any infection, injury, disease, or disorder that has been caused by or exacerbated by the performance of gender transition procedures, whether or not the gender transition procedure was performed in accordance with state and federal law or whether or not the funding for the gender transition procedure is permissible under this act; or
4. Any procedure for a male circumcision;...

Section 3. (1) *A person shall not knowingly provide gender transition procedures to any person under eighteen (18) years of age*"

BACKGROUND AND OTHER CONSIDERATIONS

BACKGROUND:

Central precocious puberty (CPP, also known as gonadotropin-dependent precocious puberty or true precocious puberty) is caused by early maturation of the hypothalamic-pituitary-gonadal axis. It is characterized by sequential maturation of breasts and pubic hair in girls, and maturation of the testes, penis, and pubic hair in boys. CPP is idiopathic in 80 to 90 percent of cases in girls, whereas intracranial lesions are detected in 40 to 75 percent of boys with CPP. Of note, there are robust data behind use of leuprolide for CPP showing puberty suppression and tolerated well. Triptorelin pamoate shows suppression of puberty in over 95 percent of children after 6 to 12 months of treatment; however, the effects on estradiol and testosterone were not consistent compared to those administered monthly dose in trials. Usual course of treatment continues until the child has reached expected adult height.

CONTRAINDICATIONS/EXCLUSIONS/DISCONTINUATION:

All other uses of Triptodur (triptorelin pamoate) are considered experimental/investigational and therefore, will follow Molina's Off- Label policy. Contraindications to Triptodur (triptorelin pamoate) include: hypersensitivity reactions, and pregnancy.

Molina Healthcare, Inc. confidential and proprietary © 2024

This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare. This page contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with Molina Healthcare.

Drug and Biologic Coverage Criteria

OTHER SPECIAL CONSIDERATIONS:

Must only be administered by a healthcare provider.

CODING/BILLING INFORMATION

Note: 1) This list of codes may not be all-inclusive. 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement

HCPCS CODE	DESCRIPTION
J3316	Injection, triptorelin, extended-release 3.75mg

AVAILABLE DOSAGE FORMS:

Triptodur SRER 22.5MG

REFERENCES

1. Triptodur (triptorelin) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; November 2023
2. Klein K, et al. Efficacy and safety of triptorelin 6-month formulation in members with central precocious puberty. *J Pediatr Endocrinol Metab.* 2016;29(11):1241- 1248
3. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin releasing hormone analogs in children. *Pediatrics.* 2009;123(4):e752.
4. Brito VN, Spinola-Castro AM, Kochi C, et al. Central precocious puberty: revisiting the diagnosis and therapeutic management. *Arch Endocrinol Metab.* 2016 Apr;60(2):163- 72
5. Kaplowitz, P., Bloch, C., & Endocrinology, the S. O. (2016). Evaluation and Referral of Children With Signs of Early Puberty. *Pediatrics*, 137(1). <https://doi.org/10.1542/peds.2015-3732>

SUMMARY OF REVIEW/REVISIONS	DATE
REVISION- Notable revisions: References	Q3 2024
REVISION- Notable revisions: Required Medical Information Quantity Appendix Contraindications/Exclusions/Discontinuation Other Special Considerations References	Q3 2023
REVISION- Notable revisions: Diagnosis Required Medical Information Continuation of Therapy	Q3 2022
Q2 2022 Established tracking in new format	Historical changes on file